heparan sulphate-based drugs

Drug Discovery Today  Volume 16, Numbers 15/16  August 2011

ERRATA

Errata

Erratum to: Heparin/heparan sulphate-based drugs Neha S. Gandhi1 and Ricardo L. Mancera1,2,* 1

Curtin Health Innovation Research Institute, Western Australian Biomedical Research Institute, School of Biomedical Sciences, Curtin University, GPO Box U1987, Perth, WA 6845, Australia 2 School of Pharmacy, Curtin University, GPO Box U1987, Perth, WA 6845, Australia

We have discovered a small mistake in the chemical structure of a drug molecule shown in Fig. 3 of our recently published paper. The correct structure for Fig. 3 is given below. OSO3-

MeO

OSO3

-O C 2

O O

OMe O

O

O

O OMe MeO

OSO3-

-O C 2

-

O -O SO 3

OMe

O

O

O OSO3-

MeO OSO3-

MeO

O O

O

O H N

O O

OMe

N

N H

N H

H N

O H

O

HN O

HN

S

S

O O

O N H

O H

NH2

HN O

+H N 2

Drug Discovery Today

FIG. 3

Chemical structures of EP217609 and EP42675. EP42675 and EP217609 are the first representatives of a new class of synthetic, parenteral anticoagulants with a dual mechanism of action combining the properties of an indirect FXa inhibitor and a direct thrombin inhibitor. The structure of EP42675 can be inferred by deleting the biotin and lysine moieties (shown in dotted rectangles) from the structure of EP217609.

DOI of original article: 10.1016/j.drudis.2010.10.009 Corresponding author:. Mancera, R.L. ([email protected]) 1359-6446/06/$ - see front matter ß 2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.drudis.2011.02.009

www.drugdiscoverytoday.com

741